Rating on Atricure (NASDAQ:ATRC) is Set to Buy. Its Keeps by Needham with $39 Target.

AtriCure, Inc. (NASDAQ:ATRC) Corporate Logo

Big Money Sentiment increased to 1.58 in 2018 Q3. It has change of 0.20, from 2018Q2’s 1.38. The ratio improved due to AtriCure, Inc. positioning: 6 sold and 34 reduced. 27 funds amassed stakes and 36 increased stakes. Investors holded 28.28 million in 2018Q2 but now own 27.72 million shares or 1.99% less.

First Manhattan owns 0% invested in AtriCure, Inc. (NASDAQ:ATRC) for 1,000 shs. Optimum Inv Advsr invested 0.01% of its capital in AtriCure, Inc. (NASDAQ:ATRC). Moreover, Aqr Capital Mgmt Ltd Com has 0% invested in AtriCure, Inc. (NASDAQ:ATRC). Emerald Advisers Pa has 478,696 shs for 0.62% of their capital. Victory Cap reported 3,759 shs. Regions Fin Corp owns 1,251 shs or 0% of their US capital. United Capital Financial Advisers Ltd Liability Corp accumulated 0% or 20,004 shs. Citadel Advsrs Ltd Limited Liability Company reported 0% of its capital in AtriCure, Inc. (NASDAQ:ATRC). 154,453 were accumulated by Quantum Capital Mgmt. Secor Cap Limited Partnership stated it has 0.03% in AtriCure, Inc. (NASDAQ:ATRC). Invesco Ltd owns 17,385 shs for 0% of their capital. 12,578 are held by Keybank National Association Oh. Wasatch Advisors accumulated 399,789 shs. Wellington Mngmt Grp Limited Liability Partnership owns 3.22 million shs or 0.02% of their US capital. Art Advsr Ltd has invested 0.04% of its capital in AtriCure, Inc. (NASDAQ:ATRC).

Reiterated Atricure (NASDAQ:ATRC) Rating.

On Friday, 1 March Needham have a $39 price target on Atricure (NASDAQ:ATRC). A upside potential of 26.75 % have this price target. The $1.19B market cap company have Buy stock rating disclosed in a note.

AtriCure, Inc. (NASDAQ:ATRC) Ratings Coverage

Total analysts of 2 have positions in AtriCure (NASDAQ:ATRC) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 9, 2018 according to StockzIntelligence Inc AtriCure has 2 analyst reports. On Tuesday, October 9 the company was maintained by Canaccord Genuity. In Friday, March 1 report Needham maintained it with “Buy” rating and $39 target.

ATRC is touching $30.77 during the last trading session, after decreased 3.66%.AtriCure, Inc. is uptrending after having risen 74.21% since March 2, 2018. ATRC has 336,331 volume or 68.42% up from normal. ATRC outperformed the S&P 500 by 74.21%.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally.The company has $1.19 billion market cap. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.Last it reported negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

For more AtriCure, Inc. (NASDAQ:ATRC) news brought out briefly go to: , Globenewswire.com, Globenewswire.com, Seekingalpha.com or Bizjournals.com. The titles are as follows: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs – Yahoo Finance” brought out on February 22, 2019, “Recent Analysis Shows Textron, Occidental Petroleum, AtriCure, Chegg, KBR, and VF Market Influences — Renewed Outlook, Key Drivers of Growth – GlobeNewswire” on January 28, 2019, “Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure — What Drives Growth in Today’s Competitive Landscape – GlobeNewswire” with a publish date: November 12, 2018, “AtriCure’s (ATRC) CEO Mike Carrel on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “These were the best Cincinnati stocks in 2018 – Cincinnati Business Courier” with publication date: January 02, 2019.

AtriCure, Inc. (NASDAQ:ATRC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.